KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Gross Margin (2016 - 2025)

Biogen has reported Gross Margin over the past 17 years, most recently at 78.26% for Q4 2025.

  • Quarterly results put Gross Margin at 78.26% for Q4 2025, up 203.0% from a year ago — trailing twelve months through Dec 2025 was 75.69% (down 43.0% YoY), and the annual figure for FY2025 was 75.69%, down 43.0%.
  • Gross Margin for Q4 2025 was 78.26% at Biogen, up from 73.39% in the prior quarter.
  • Over the last five years, Gross Margin for BIIB hit a ceiling of 94.0% in Q4 2021 and a floor of 73.09% in Q1 2023.
  • Median Gross Margin over the past 5 years was 78.06% (2025), compared with a mean of 80.5%.
  • Biggest five-year swings in Gross Margin: surged 1120bps in 2021 and later plummeted -1690bps in 2024.
  • Biogen's Gross Margin stood at 94.0% in 2021, then dropped by 0bps to 93.55% in 2022, then fell by 0bps to 93.13% in 2023, then dropped by -18bps to 76.23% in 2024, then rose by 3bps to 78.26% in 2025.
  • The last three reported values for Gross Margin were 78.26% (Q4 2025), 73.39% (Q3 2025), and 77.13% (Q2 2025) per Business Quant data.